Treatment of pretibial myxedema with intralesional immunomodulating therapy

References

• KrissJPPathogenesis and treatment of pretibial myxedemaEndocrinol Metab Clin North Am19871624094153319589
   PubMed Web of Science ®Google Scholar
• BartalenaLTandaMLClinical practice. Graves’ ophthalmopathyN Engl J Med200936010994100119264688
   PubMed Web of Science ®Google Scholar
• FatourechiVThyroid dermopathy and acropachyBest Pract Res Clin Endocrinol Metab201226455356522863396
   PubMed Web of Science ®Google Scholar
• CannavoSPBorgiaFVaccaroMGuarneriFMaglioloEGuarneriBPretibial myxoedema associated with Hashimoto’s thyroiditisJ Eur Acad Dermatol Venereol200216662562712482050
   PubMed Web of Science ®Google Scholar
• GeorgalaSKatoulisACGeorgalaCKatoulisECHatziolouEStavrianeasNGPretibial myxedema as the initial manifestation of Graves’ diseaseJ Eur Acad Dermatol Venereol200216438038312224697
   PubMed Web of Science ®Google Scholar
• BartalenaLFatourechiVExtrathyroidal manifestations of Graves’ disease: a 2014 updateJ Endocrinol Invest201437869170024913238
   PubMed Web of Science ®Google Scholar
• FatourechiVPretibial myxedema: pathophysiology and treatment optionsAm J Clin Dermatol20056529530916252929
   PubMed Web of Science ®Google Scholar
• RiceSAPedenNRMcGlynnSMortonCAtypical presentation of infiltrative thyroid dermopathyClin Exp Dermatol2010351565819508564
   PubMed Web of Science ®Google Scholar
• NoppakunNBancheunKChandraprasertSUnusual locations of localized myxedema in Graves’ disease. Report of three casesArch Dermatol1986122185883753644
   PubMedGoogle Scholar
• DhailleFDadbanAMezianeLElephantiasic pretibial myxoedema with upper-limb involvement, treated with low-dose intravenous immunoglobulinsClin Exp Dermatol201237330730822007759
   PubMed Web of Science ®Google Scholar
• CaoYZhuHJZhengHYLiJMyxedemaLancet Diabetes Endocrinol20142760024931819
   PubMed Web of Science ®Google Scholar
• MinutoliFBenedettoCVisalliCGranataAGaetaMComputed tomography and magnetic resonance imaging findings of ureteral myxedema in Graves’ diseaseClin Imaging201539471171325766333
   PubMed Web of Science ®Google Scholar
• LohiyaSLohiyaVStahlEJPretibial myxedema without ophthalmopathy: an initial presentation of Graves’ diseaseAm J Med Sci20133461737523514670
   PubMed Web of Science ®Google Scholar
• SieglerMRefetoffSPretibial myxedema – a reversible cause of foot drop due to entrapment of the peroneal nerveN Engl J Med197629425138313841264177
   PubMed Web of Science ®Google Scholar
• HerskovitzIHughesOMacQuhaeFKirsnerRSPretibial myxedema masquerading as a venous leg ulcerWounds2017293777928355140
   PubMed Web of Science ®Google Scholar
• ZhouHSabbaghMWymanRLiebsackCKunikMENajafiBInstrumented trail-making task to differentiate persons with no cognitive impairment, amnestic mild cognitive impairment, and Alzheimer disease: a proof of concept studyGerontology201763218920027855415
   PubMed Web of Science ®Google Scholar
• BilenHAtasoyMAkcayGElephantiasic pretibial myxedema and cutis verticis gyrata caused by Graves’ diseaseThyroid200616881581616910888
   PubMed Web of Science ®Google Scholar
• LuY-YWeiK-CElephantiasic pretibial myxedemaIntern Med201251192837283723037487
   PubMed Web of Science ®Google Scholar
• VannucchiGCampiICovelliDForzenigoLBeck-PeccozPSalviMTreatment of pretibial myxedema with dexamethasone injected subcutaneously by mesotherapy needlesThyroid201323562663223397966
   PubMed Web of Science ®Google Scholar
• SusserWSHeermansAGChapmanMSBaughmanRDElephantiasic pretibial myxedema: a novel treatment for an uncommon disorderJ Am Acad Dermatol200246572372612004314
   PubMed Web of Science ®Google Scholar
• LanCLiCChenWMeiXZhaoJHuJA randomized controlled trial of intralesional glucocorticoid for treating pretibial myxedemaJ Clin Med Res201571186287226491499
   PubMedGoogle Scholar
• RamosLOMattosPCFigueredoGLMaiaAARomeroSAPre-tibial myxedema: treatment with intralesional corticosteroidAn Bras Dermatol2015903 Suppl 1143146
   PubMed Web of Science ®Google Scholar
• SchwartzKMFatourechiVAhmedDDPondGRDermopathy of Graves’ disease (pretibial myxedema): long-term outcomeJ Clin Endocrinol Metab200287243844611836263
   PubMed Web of Science ®Google Scholar
• TakasuNHigaHKinjouYTreatment of pretibial myxedema (PTM) with topical steroid ointment application with sealing cover (Steroid Occlusive Dressing Technique: Steroid ODT) in Graves’ PatientsIntern Med201049766566920371956
   PubMed Web of Science ®Google Scholar
• DengASongDMultipoint subcutaneous injection of long-acting glucocorticoid as a cure for pretibial myxedemaThyroid2011211838521162684
   PubMed Web of Science ®Google Scholar
• JollesSHughesJUse of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedemaInt Immunopharmacol20066457959116504920
   PubMed Web of Science ®Google Scholar
• ShihSRLinMSLiHYObserving pretibial myxedema in patients with Graves’ disease using digital infrared thermal imaging and high-resolution ultrasonography: for better records, early detection, and further investigationEur J Endocrinol2011164460561121266550
   PubMed Web of Science ®Google Scholar
• YuHJiangXPanMHuangRElephantiasic pretibial myxedema in a patient with graves disease that resolved after 131I treatmentClin Nucl Med201439875875924830877
   PubMed Web of Science ®Google Scholar
• KimWBMistryNAlaviASibbaldCSibbaldRGPretibial myxedema: case presentation and review of treatment optionsInt J Low Extrem Wounds201413215215424807996
   PubMed Web of Science ®Google Scholar
• KamathCYoungSKabelisKThyrotrophin receptor antibody characteristics in a woman with long-standing Hashimoto’s who developed Graves’ disease and pretibial myxoedemaClin Endocrinol (Oxf)201277346547022891608
   PubMed Web of Science ®Google Scholar
• Hadj-KacemHRebuffatSMnif-FekiMBelguith-MaalejSAyadiHPeraldi-RouxSAutoimmune thyroid diseases: genetic susceptibility of thyroid-specific genes and thyroid autoantigens contributionsInt J Immunogenet2009362859619284442
   PubMed Web of Science ®Google Scholar
• ShinoharaMHamasakiYKatayamaIRefractory pretibial myxoedema with response to intralesional insulin-like growth factor 1 antagonist (octreotide): downregulation of hyaluronic acid production by the lesional fibroblastsBr J Dermatol200014351083108611069527
   PubMed Web of Science ®Google Scholar
• HeyesCNolanRLeahyMGebauerKTreatment-resistant elephantiasic thyroid dermopathy responding to rituximab and plasmapheresisAustralas J Dermatol2012531e1e422309343
   PubMed Web of Science ®Google Scholar